Barrington lowered the firm’s price target on HealthEquity (HQY) to $110 from $125 and keeps an Outperform rating on the shares following the Q4 report. The company topped expectations and raised its fiscal 2027 revenue and adjusted EBITDA guidance, the analyst tells investors in a research note. Barrington believes HealthEquity remains well positioned to benefit from health savings account market expansion.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY: